BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 16183853)

  • 1. Allosteric binding sites on muscarinic acetylcholine receptors.
    Wess J
    Mol Pharmacol; 2005 Dec; 68(6):1506-9. PubMed ID: 16183853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interactions of orthosteric and allosteric ligands with [3H]dimethyl-W84 at the common allosteric site of muscarinic M2 receptors.
    Tränkle C; Weyand O; Voigtländer U; Mynett A; Lazareno S; Birdsall NJ; Mohr K
    Mol Pharmacol; 2003 Jul; 64(1):180-90. PubMed ID: 12815174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atypical muscarinic allosteric modulation: cooperativity between modulators and their atypical binding topology in muscarinic M2 and M2/M5 chimeric receptors.
    Tränkle C; Dittmann A; Schulz U; Weyand O; Buller S; Jöhren K; Heller E; Birdsall NJ; Holzgrabe U; Ellis J; Höltje HD; Mohr K
    Mol Pharmacol; 2005 Dec; 68(6):1597-610. PubMed ID: 16157694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel multivalent ligand that bridges the allosteric and orthosteric binding sites of the M2 muscarinic receptor.
    Steinfeld T; Mammen M; Smith JA; Wilson RD; Jasper JR
    Mol Pharmacol; 2007 Aug; 72(2):291-302. PubMed ID: 17478612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a radioligand, [(3)H]LY2119620, to probe the human M(2) and M(4) muscarinic receptor allosteric binding sites.
    Schober DA; Croy CH; Xiao H; Christopoulos A; Felder CC
    Mol Pharmacol; 2014 Jul; 86(1):116-23. PubMed ID: 24807966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and characterization of orthosteric and allosteric muscarinic M2 acetylcholine receptor ligands by affinity selection-mass spectrometry.
    Whitehurst CE; Nazef N; Annis DA; Hou Y; Murphy DM; Spacciapoli P; Yao Z; Ziebell MR; Cheng CC; Shipps GW; Felsch JS; Lau D; Nash HM
    J Biomol Screen; 2006 Mar; 11(2):194-207. PubMed ID: 16490772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of a kinetic model to the apparently complex behavior of negative and positive allosteric modulators of muscarinic acetylcholine receptors.
    Avlani V; May LT; Sexton PM; Christopoulos A
    J Pharmacol Exp Ther; 2004 Mar; 308(3):1062-72. PubMed ID: 14711931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modes of allosteric interactions with free and [3H]N-methylscopolamine-occupied muscarinic M2 receptors as deduced from buffer-dependent potency shifts.
    Schröter A; Tränkle C; Mohr K
    Naunyn Schmiedebergs Arch Pharmacol; 2000 Dec; 362(6):512-9. PubMed ID: 11138843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First gallamine-tacrine hybrid: design and characterization at cholinesterases and the M2 muscarinic receptor.
    Elsinghorst PW; Cieslik JS; Mohr K; Tränkle C; Gütschow M
    J Med Chem; 2007 Nov; 50(23):5685-95. PubMed ID: 17944454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Binding of orthosteric ligands to the allosteric site of the M(2) muscarinic cholinergic receptor.
    Redka DS; Pisterzi LF; Wells JW
    Mol Pharmacol; 2008 Sep; 74(3):834-43. PubMed ID: 18552124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-function studies of allosteric agonism at M2 muscarinic acetylcholine receptors.
    May LT; Avlani VA; Langmead CJ; Herdon HJ; Wood MD; Sexton PM; Christopoulos A
    Mol Pharmacol; 2007 Aug; 72(2):463-76. PubMed ID: 17525129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Probe dependence in the allosteric modulation of a G protein-coupled receptor: implications for detection and validation of allosteric ligand effects.
    Valant C; Felder CC; Sexton PM; Christopoulos A
    Mol Pharmacol; 2012 Jan; 81(1):41-52. PubMed ID: 21989256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allosteric site in M2 acetylcholine receptors: evidence for a major conformational change upon binding of an orthosteric agonist instead of an antagonist.
    Grossmüller M; Antony J; Tränkle C; Holzgrabe U; Mohr K
    Naunyn Schmiedebergs Arch Pharmacol; 2006 Jan; 372(4):267-76. PubMed ID: 16362429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allosteric ligands for G protein-coupled receptors: a novel strategy with attractive therapeutic opportunities.
    De Amici M; Dallanoce C; Holzgrabe U; Tränkle C; Mohr K
    Med Res Rev; 2010 May; 30(3):463-549. PubMed ID: 19557759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allosteric properties of G protein-coupled receptor oligomers.
    Springael JY; Urizar E; Costagliola S; Vassart G; Parmentier M
    Pharmacol Ther; 2007 Sep; 115(3):410-8. PubMed ID: 17655934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction studies of multiple binding sites on m4 muscarinic acetylcholine receptors.
    Lanzafame AA; Sexton PM; Christopoulos A
    Mol Pharmacol; 2006 Aug; 70(2):736-46. PubMed ID: 16709648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of M2 muscarinic acetylcholine receptor expression and signaling by prolonged exposure to allosteric modulators.
    May LT; Lin Y; Sexton PM; Christopoulos A
    J Pharmacol Exp Ther; 2005 Jan; 312(1):382-90. PubMed ID: 15333678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of an "Allosteric Site-Impaired" M
    Moo EV; Sexton PM; Christopoulos A; Valant C
    Mol Pharmacol; 2018 Nov; 94(5):1298-1309. PubMed ID: 30213802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allosteric site on muscarinic acetylcholine receptors: identification of two amino acids in the muscarinic M2 receptor that account entirely for the M2/M5 subtype selectivities of some structurally diverse allosteric ligands in N-methylscopolamine-occupied receptors.
    Voigtländer U; Jöhren K; Mohr M; Raasch A; Tränkle C; Buller S; Ellis J; Höltje HD; Mohr K
    Mol Pharmacol; 2003 Jul; 64(1):21-31. PubMed ID: 12815157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of Conserved Tyrosine Lid Residues in the Activation of the M
    Pham V; Habben Jansen MCC; Thompson G; Heitman LH; Christopoulos A; Thal DM; Valant C
    Mol Pharmacol; 2023 Sep; 104(3):92-104. PubMed ID: 37348914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.